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Washington, DC 20001, USADeveloping country vaccine manufacturers, so-called “emerg-
ng suppliers”, have made enormous strides over the last two
ecades. They have increased capacity, improved facilities and
re developing new important products [1–5]. Developing country
anufacturers now provide over half of all vaccines used glob-
lly. Their early activities concentrated on the manufacture of
he standard World Health Organization/Expanded Programme on
mmunization (WHO/EPI) antigens (diphtheria, tetanus, pertussis,
ral polio vaccines, measles and BCG) for local consumption, but
ver the last 15 years several developing country manufacturers
ave worked with WHO  and the United Nations Children’s Fund
UNICEF) to ofﬁcially “prequalify” their products for global distri-
ution. These emerging suppliers are exploring partnerships with
ultinationals and other partners as they seek to expand the prod-
cts they can offer both locally and globally. The papers grouped
n this special issue of Vaccine offer an excellent example of their
exibility and their potential in meeting global vaccine needs.
In  the mid  2000s a global shortfall in inﬂuenza vaccine was
pparent and it was clear that production had to be expanded to
nsure that developing countries could have access to pandemic
nﬂuenza vaccines. Improving inﬂuenza vaccine production within
eveloping countries was an important global public health prior-
ty to assure better preparation should a pandemic occur. A major
hallenge was the need for rapid technology transfer to enable
his production capacity. Since 2008, WHO  has provided 11 seed
rants to manufacturers in low- and middle-income countries to
stablish or improve their pandemic inﬂuenza vaccine production
apacities. The attached papers describe the success of this effort
nd provide an example of the potential that is available with
eveloping country vaccine manufacturers if a speciﬁc initiative is
ell organized and led. Using a world class group of advisers, WHO
as facilitated technology transfer from established manufacturers
r other technical sources for the rapid expansion of egg-based
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Open access under CC BY-NC-ND license.killed  and live attenuated inﬂuenza vaccines. An important
component of this work was the establishment of a technology
platform at the Netherlands Vaccine Institute (NVI) that provides
training and technology transfer for egg-based inactivated whole
and split virus inﬂuenza A vaccine production to participants from
developing countries (NVI paper). Predictably, some programmes
are progressing more speedily than others, but the overall progress
in improving global inﬂuenza vaccine capacity is clearly apparent
in the collected papers. The success of this programme offers a
model for efﬁciently increasing global access to inﬂuenza as well
as and other vaccines.
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